Sommerauer Christina, Kaushik Neha, Woodham Adrine, Renom-Guiteras Anna, Martinez Yolanda V, Reeves David, Kunnamo Ilkka, Al Qur An Thekraiat, Hübner Steffen, Sönnichsen Andreas
Institute of General Practice and Family Medicine, University of Witten/Herdecke, Alfred-Herrhausen-Straße 50, 58448, Witten, Germany.
University of Manchester, Centre for Primary Care, Institute of Population Health, Manchester, UK.
BMC Geriatr. 2017 Oct 16;17(Suppl 1):228. doi: 10.1186/s12877-017-0576-3.
Thiazides are commonly prescribed to older people for the management of hypertension. The objective of this study was to identify the evidence on the risks and benefits of their use among adults aged ≥65 years and to develop recommendations to reduce potentially inappropriate use.
Systematic review (SR) of the literature covering six databases. We applied a staged search approach, where each search was undertaken only if the previous one did not yield high quality results. Searches 1 and 2 identified relevant SRs and meta-analyses published up to December 2015 from all databases. Search 3 identified additional individual interventional studies (IS) and observational studies (OS) not identified by the preceding searches. We included all studies evaluating the effect of thiazides on patient-relevant outcomes in the management of hypertension with a sufficient number of participants aged ≥65 years or a subgroup analysis based on age. Two independent reviewers extracted data and carried out quality appraisal. Recommendations were developed using the GRADE methodology.
Searches 1 to 3 were performed. We included 34 articles reporting on 12 IS and 4 OS. Mean ages ranged from 59 to 83.8 years. Four studies had performed a subgroup analysis by age. Information on comorbidity, polypharmacy and frailty of the participants was scarce or not available. The IS compared thiazides to placebo or other antihypertensive drugs and evaluated cardiovascular endpoints or all-cause-mortality as primary outcomes. The OS investigated the association between thiazide use and the risk of gout, fractures and adverse effects. Our results suggest that thiazides are efficacious in preventing cardiovascular events for this population group. Low-dose regimens of thiazides may be safer than high-dose (low quality of evidence), and a history of gout may increase the risk of adverse events (low quality of evidence). Three recommendations were developed.
The use of low dose treatment with thiazides for the management of hypertension in adults aged 65 and older seems justified, unless a history of gout is present. The quality of the evidence is low and studies rarely describe characteristics of the participants such as polypharmacy and frailty. Further good quality studies are needed.
噻嗪类药物常用于老年人高血压的治疗。本研究的目的是确定≥65岁成年人使用噻嗪类药物的风险和益处的证据,并制定减少潜在不适当使用的建议。
对涵盖六个数据库的文献进行系统评价(SR)。我们采用分阶段搜索方法,只有在前一次搜索未产生高质量结果时才进行下一次搜索。搜索1和2确定了截至2015年12月从所有数据库中发表的相关系统评价和荟萃分析。搜索3确定了之前搜索未识别的其他个体干预研究(IS)和观察性研究(OS)。我们纳入了所有评估噻嗪类药物对高血压管理中与患者相关结局的影响的研究,这些研究有足够数量的≥65岁参与者或基于年龄的亚组分析。两名独立评审员提取数据并进行质量评估。使用GRADE方法制定建议。
进行了搜索1至3。我们纳入了34篇报告12项干预研究和4项观察性研究的文章。平均年龄范围为59至83.8岁。四项研究进行了年龄亚组分析。关于参与者的合并症、多重用药和虚弱的信息很少或没有。干预研究将噻嗪类药物与安慰剂或其他抗高血压药物进行比较,并将心血管终点或全因死亡率作为主要结局进行评估。观察性研究调查了噻嗪类药物使用与痛风、骨折和不良反应风险之间的关联。我们的结果表明,噻嗪类药物对该人群预防心血管事件有效。低剂量噻嗪类药物方案可能比高剂量更安全(证据质量低),痛风病史可能增加不良事件风险(证据质量低)。制定了三项建议。
对于65岁及以上成年人,使用低剂量噻嗪类药物治疗高血压似乎是合理的,除非有痛风病史。证据质量较低,研究很少描述参与者的特征,如多重用药和虚弱。需要进一步的高质量研究。